Live feed08:30:00·4mPRReleasevia QuantisnowAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCByQuantisnow·Wall Street's wire, on your screen.ABBV· AbbVie Inc.Health Care
